N/A N=119 A Study of Patients With Lower Extremity Acute Limb Ischemia to Remove Thrombus With the Indigo Aspiration System
Lower Extremity Acute Limb Ischemia · LE ALI
Primary: Target Limb Salvage Rate — 109 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=53 Switch to Ticagrelor in Critical Limb Ischemia Anti-platelet Study
Critical Limb Ischemia
Primary: To Determine Platelet Inhibition Before and After Switching for Two Weeks From Clopidogrel to Ticagrelor in Patients With CLI. — 173; 140; 71; 63 P2Y12 reaction units…
N/A N=358 Study of IN.PACT Amphirion™ Drug Eluting Balloon vs. Standard PTA for the Treatment of Below the Knee Critical Limb Ischemia
Critical Lower Limb Ischemia
Primary: Late Lumen Loss (LLL) of the Target Lesion by Quantitative Vascular Angiography (QVA) — 0.605; 0.616 mm
N/A N=100 Aspirin and Clopidogrel Reactivity in Patients With Critical Limb Ischemia (CLI)
Critical Limb Ischemia
Primary: Asses the Prevalence of High On-treatment Platelet Reactivity in Critical Limb Ischemia Patients Treated With Aspirin and Clopidogrel. — 18; 17; 8; 57 Participants
Phase 2 N=67 ACP-01 in Patients With Critical Limb Ischemia
Critical Limb Ischemia
Primary: Wound Size, Amputation or Survival — 12; 3 participants — p=0.258
N/A N=28 Percutaneous Deep Vein Arterialization Post-Market Study
Critical Limb Ischemia
Primary: Amputation-free Survival — 67.2 percentage of participants
N/A N=32 PROMISE I Early Feasibility Trial of the LimFlow Stent Graft System
Critical Limb Ischemia · Chronic Limb-Threatening Ischemia
Primary: Amputation-free Survival — 90.6 Percentage of participants
N/A N=34 PROMISE International
Critical Limb Ischemia
Primary: Amputation-free Survival — 50.7 percentage of participants
Phase 2 N=20 Pilot Study to Examine the Use of Rivaroxaban After Angioplasty for Critical Limb Ischemia
Critical Limb Ischemia
Primary: Reintervention, Above Ankle Amputation and Restenosis (RAS) — 7; 4 Participants
N/A N=51 Complete Lesion Assessment With ffR and IVUS TechnologY
Peripheral Artery Disease · Critical Limb Ischemia
Primary: Percentage of Calcium Removal Out of Lumen Gain as Assessed by IVUS — 25.0; 0.0 percentage of lumen gain — p=0.0220
Phase 4 N=102 Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)
Peripheral Arterial Disease
Primary: Effect of Intensive Lipid Modification Medication Therapy on Progression of Atherosclerosis and Restenosis of Femoral Arteries Measured Using High Resolution Magnetic…
Phase 2 N=10 A Phase IIB Pilot Study of a Modified Dosage Regimen of AMG0001 in Subjects With Critical Limb Ischemia
Critical Limb Ischemia · Vascular Diseases · Peripheral Arterial Disease
Primary: Number of Participants With Adverse Events (AEs) Suspected to be Related to Injections of AMG0001 — 1; 1; 1; 1 Participants
N/A N=305 Low InTensity Exercise Intervention in PAD
Peripheral Artery Disease
Primary: Six-minute Walk Distance — -6.4; 34.5; -15.1 meters
N/A N=15 ICG Fluorescence Imaging in Lower Extremity Amputation Patients
Trauma Injury
Primary: Total Bone Blood Flow (TBBF)-Post Osteotomy — 4.9 mL/min/100g
N/A N=129 JETi Lower Extremity Arterial Thrombosis
Arterial Thrombosis
Primary: Primary Effectiveness Endpoint - Clot Removal Grade From Pre-JETi to Post-JETi - Core Lab Assessed - Per Vessel Analysis — 36; 41; 52; 93 Vessels
Phase 3 N=153 Trial to Evaluate the Safety & Efficacy of the Omnilink Elite™ Peripheral Balloon-Expandable Stent System in Subjects With Atherosclerotic de Novo or Restenotic Lesions in the Native Common Iliac Artery and/or Native External Iliac Artery
Peripheral Vascular Disease
Primary: Major Adverse Event (MAE) — 5.4 percentage of participants
Phase 2 N=174 A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion
Acute Peripheral Arterial Occlusion
Primary: The Proportion of Subjects With >50% Thrombolysis — 43.8; 47.4; 81.0; 47.4 percentage of participants
N/A N=150 Belgian-Italian Trial to Evaluate the Efficacy and Safety of Below The Knee (BTK) Treatment With the Luminor 14 Paclitaxel Coated Percutaneous Transluminal Angioplasty Balloon Catheter of iVascular
Peripheral Arterial Disease
Primary: Primary Efficacy Endpoint: Freedom From MALE — 144 Participants
Phase 3 N=159 Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities
Peripheral Arterial Disease
Primary: Number of Participants With First Occurrence of Target Vessel Occlusion, Surgical Revascularization, Endovascular Revascularization, Major Amputation of Target Limb…
Phase 2 N=15 Technology That Permits Focal Dose of Antibiotics to be Delivered to Lower Limb(s) of Diabetic Patients
Diabetes · Infection
Primary: Efficacy of Timentin Delivered by PILP Procedure (Treatment Group) Versus Intravenous Delivery (Control Group) at Reducing Microbiological Load in Subjects With…
N/A N=121 Revolution™ Peripheral Atherectomy System for Lower Extremity Peripheral Arterial Revascularization
Peripheral Artery Disease
Primary: Safety Endpoint: Number of Participants With Freedom From Major Adverse Events — 110 Participants
N/A N=113 Treatment of Peripheral Arterial Hemorrhage With Lava LES (The LAVA Study)
Peripheral Arterial Hemorrhage
Primary: Percentage of Participants With Composite of Freedom From Major Adverse Events (MAEs) — 100 percentage of participants — p=<0.025
N/A N=799 Study of SilverHawk®/TurboHawk® in Lower Extremity Vessels (DEFINITIVE™ LE)
Peripheral Arterial Disease · Claudication · Critical Limb Ischemia
Primary: Primary Patency Rate (in Patients Treated for Claudication RCC 1-3) — 81.6 percentage of lesions by Kaplan Meier
N/A N=30 Can a Dedicated Chronic Limb-threatening Ischaemia (CLTI) Clinic Improve Patient Self-reported Quality of Life
Chronic Limb Threatening Ischemia
Primary: EuroQoL-5D Visual Acuity Scale (VAS) Score — 47.55; 69.15; 65.35 score on a scale — p=0.005
Phase 4 N=840 Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV
Peripheral Arterial Occlusive Disease
Primary: Complete Healing of Ischemic Necroses and Ulcerations at 12 Weeks After the End of Study Drug Treatment — 49; 43; 27; 30 participants — p=0.2587
Phase 4 N=131 Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Pulmonary Embolism
Pulmonary Embolism and Thrombosis
Primary: Change From Baseline in the Right Ventricle (RV) Diameter-to-Left Ventricle (LV) Diameter Ratio to 48 ± 6 Hours After the Start of the APT Procedure — 1.53; 1.47; 1.52…
N/A N=115 FlowTriever for Acute Massive Pulmonary Embolism (FLAME)
PE - Pulmonary Embolism · PE - Pulmonary Thromboembolism
Primary: Composite Incidence of All-cause Mortality, Clinical Deterioration, Bailout, and Major Bleeding — 9; 39 Participants
Phase 2 N=46 Study of LLG783 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication
Peripheral Artery Disease (PAD); Intermittent Claudication
Primary: Number of Participants With Adverse Events (AEs), Drug-related AEs, Serious Adverse Events (SAEs) and Deaths — 18; 17; 4; 4 Participants
Phase 3 N=59 ULTrasound Accelerated ThrombolysIs of PulMonAry Embolism
Submassive Pulmonary Embolism
Primary: Reduction of RV/LV Ratio — 0.03; 0.30 Ratio
Phase 3 N=6,564 Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities
Peripheral Artery Disease
Primary: Primary Efficacy Outcome: Number of Participants With Composite of Myocardial Infarction (MI), Ischemic Stroke, Cardiovascular Death, Acute Limb Ischemia (ALI) and Major…